JBC Advanced Peptides, Inc.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Danilkovitch, A.
Right arrow Articles by Leonard, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Danilkovitch, A.
Right arrow Articles by Leonard, E. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 42, 29937-29943, October 15, 1999


Interaction of Macrophage-stimulating Protein with Its Receptor
RESIDUES CRITICAL FOR beta  CHAIN BINDING AND EVIDENCE FOR INDEPENDENT alpha  CHAIN BINDING*

Alla DanilkovitchDagger §, Maria Miller, and Edward J. LeonardDagger

From the Dagger  Laboratory of Immunobiology, NCI-Frederick Cancer Research and Development Center and  Macromolecular Structure Laboratory, NCI-Frederick Cancer Research and Development Center, ABL-Basic Research Program, Frederick, Maryland 21702

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Macrophage-stimulating protein (MSP) and hepatocyte growth factor/scatter factor (HGF/SF) are plasminogen-related growth and motility factors that interact with cell-surface protein tyrosine kinase receptors. Each one is a heterodimeric protein comprising a disulfide-linked alpha  chain and a serine protease-like beta  chain. Despite structural similarities between MSP and HGF, the primary receptor binding site is located on the alpha  chain of HGF/SF but on the beta  chain of MSP. To obtain insight into the structural basis for MSP beta  chain binding, beta  chain structure was modeled from coordinates of an existing model of the HGF beta  chain. The model revealed that the region corresponding to the S1 specificity pocket in trypsin is filled by the Asn682/Glu648 interacting pair, leaving a shallow cavity for possible beta  chain interaction with the receptor. Mutants in this region were created, and their binding characteristics were determined. A double mutation of Asn682/Glu648 caused diminished binding of the beta  chain to the MSP receptor, and a single mutation of neighboring Arg683 completely abolished binding. Thus, this region of the molecule is critical for binding. We also found that at equimolar concentrations of free alpha  and beta  chains, alpha  chain binding to receptor was detectable, at levels considerably lower than beta  chain binding. The EC50 values determined by quantitative enzyme-linked immunosorbent assay are 0.25 and 16.9 nM for beta  and alpha  chain, respectively. The data suggest that MSP has two independent binding sites with high and low affinities located in beta  and alpha  chain, respectively, and that the two sites together mediate receptor dimerization and subsequent activation.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Macrophage-stimulating protein (MSP)1 is a 78-kDa growth and motility factor that belongs to a plasminogen-related kringle protein family (1, 2). It is most closely related to hepatocyte growth factor/scatter factor (HGF/SF), to which it has 45% sequence similarity (3). Mature MSP acts on a number of cell types including tissue macrophages, epithelia, and hematopoietic cells (4). Actions on macrophages include stimulation of motility (5), induction of phagocytosis of serum complement-coated erythrocytes (1), inhibition of inducible NO synthase up-regulation by inflammatory stimuli (6), and induction of interleukin 6 secretion.2 MSP induces adhesion, motility, and replication of epithelial cells, and it can prevent the apoptosis that occurs when epithelial cells are prevented from attachment to a substrate (7). MSP mediates its effects by binding to and activating a cell receptor tyrosine kinase known as RON in humans (8, 9) and STK in mice (10, 11). Closely related HGF/SF also has mitogenic and motogenic actions on epithelial cell types (12) that express Met, the specific receptor for this ligand (13). HGF has a morphogenetic role in development and tissue repair (14). Specific mutations in Met are oncogenic in both experimental models (for a review see Ref. 15) and in sporadic human cancers (16).

In contrast to other members of this plasminogen-related family, which are serine proteases, MSP and HGF are devoid of enzymatic activity because of catalytic triad mutations. However, they have retained the proteolytic mechanism of activation of the zymogens of the family (17). Thus, MSP is synthesized by hepatocytes (18) as biologically inactive single chain pro-MSP and is converted at extravascular sites to active MSP by trypsin-like proteases, which cleave at Arg483/Val484 (19) to make a disulfide-linked alpha beta chain heterodimer (20). MSP and HGF have 40% sequence similarity to plasminogen and the same domain organization. The three proteins evolved from a common ancestor (21). Features of the alpha  chain of MSP and HGF include an N-terminal domain (N domain) corresponding to the plasminogen preactivation peptide, four kringles, and a segment that terminates in the cleavage site for activation; the beta  chain is the serine protease-like domain. HGF binds with high affinity to its receptor via the alpha  chain. The N domain makes a critical contribution to HGF binding, since N domain deletion mutants have reduced or absent biological activity (22, 23) and fail to inhibit binding of HGF to Met-expressing target cells (23). In contrast to HGF, studies with 125I-labeled subunits of MSP showed that the beta  chain bound with high affinity to RON, whereas alpha  chain binding was undetectable (24). Mutant MSP lacking the beta  chain is biologically inactive (25). Therefore, despite the similarity in domains of HGF and MSP, the loci for high affinity binding to their receptors are completely different.

To explore the basis of MSP beta  chain binding to RON, we took advantage of a recently published energy-minimized three-dimensional model of the beta  chain of HGF (21). We used the HGF model coordinates to make a comparable model of the MSP beta  chain to look for features that might account for its binding properties. By analogy to proteases, MSP and HGF correspond to enzymes, and their receptors correspond to enzyme substrates. From this viewpoint, regions of the MSP serine protease-like domain of particular interest for binding to receptor would include the catalytic site and several surface loops that define the substrate binding cleft for chymotrypsin-like proteases (26). Our model of the MSP beta  chain revealed features that were postulated to account for its binding to RON. Mutagenesis studies reported herein established that the region corresponding to an enzyme S1 site is essential for beta  chain binding to RON.

Our experiments also revealed binding to RON-expressing cells of MSP-free alpha  chain, which was a small fraction of the amount of beta  chain binding. This suggests that MSP has two receptor binding sites, a high affinity site in the beta  chain and a low affinity site in the alpha  chain. The result supports a recent hypothesis that ligand-induced RON dimerization by MSP is mediated by a single ligand molecule, which binds to a receptor via the beta  chain, after which a second receptor is engaged by the alpha  chain (27).

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Human recombinant MSP and free alpha  and beta  chains were from Toyobo (Osaka, Japan) and R & D Systems (Minneapolis, MN). Rabbit and mouse anti-MSP antibodies were described (28). Madin-Darby canine kidney (MDCK) and CHO-K1 cells were from ATCC (Manassas, VA). MDCK cells stably transfected with a human RON cDNA (clone RE7) were described (9).

Modeling of the MSP beta  Chain-- Inasmuch as the MSP beta  chain has 48% amino acid identity to the HGF beta  chain, we used the coordinates of the three-dimensional model of the HGF beta  chain (21) to model the MSP beta  chain structure. Side chains of HGF were replaced with MSP side chains according to the alignment shown in Fig. 1. Positions of the conserved backbone atoms were not altered. The loop comprising residues 525-533 was modeled to reflect the experimentally demonstrated disulfide bridge between Cys527 and Cys562 (19). Subsequently the positions of several side chains were adjusted manually (program FRODO and its silicon graphics version TOM (29)) to remove bad contacts and to optimize electrostatic and hydrophobic interactions. The model was then energy-minimized using program XPLOR (30) employing 250 cycles of the Powell conjugate gradient algorithm.

Generation of Mutants of Wild Type Human MSP cDNA-- All mutants were generated using the pAlterII (Promega, Madison, WI) mutagenesis kit with mutagenic oligonucleotides as follows: for R683Q, GGAATTATAATCCCCAACCAAGTATGCGCAAGGTCCCGC; for E648G/D682G, ATGTGCACTGGGGGACTGTTG/ATAATCCCCGGCCGAGTATGC. For stable transfection of eukaryotic cells wild type and mutant MSP were re-cloned into pCL-neo (Promega, Madison, WI).

Cell Culture and Transfection of Recombinant MSP-- CHO-K1 cells (ATCC) were grown in Dulbecco's modified Eagle's medium supplemented with 8% fetal calf serum. For stable expression of MSP, cells in 10-cm dishes were transfected with 10 µg of MSP cDNA by Superfect reagent (Qiagen, Santa Clarita, CA) and placed in medium with 500 µg/ml geneticin (Life Technologies, Inc.). After selection, single colonies were cloned, and clones with highest equal expression of wild type and mutant MSP were selected. The concentration of recombinant MSP in culture supernatants was measured by sandwich ELISA.

Sandwich ELISA for MSP-- The concentration of secreted recombinant MSP in cell culture supernatants was determined by sandwich ELISA (28). Concentrations were calculated by reference to a standard curve generated with wild type recombinant human MSP.

Immunoprecipitation and Western Blotting-- MSP from culture supernatants was immunoprecipitated by rabbit polyclonal anti-MSP antibodies conjugated to Sepharose beads. Immunoprecipitates were washed and boiled after addition of 2× sample buffer. After PAGE, proteins were transferred to a nitrocellulose membrane (Amersham Pharmacia Biotech). MSP was detected with rabbit anti-MSP antibodies. ECL (Amersham Pharmacia Biotech) was used for visualization of the peroxidase complex.

Metabolic Labeling of MSP-- CHO-K1 cells stably expressing wild type or mutant MSP were incubated for 48 h with 35S-easy labeling mix ([35S]cysteine and [35S]methionine) (NEN Life Science Products) in methionine- and cysteine-free Dulbecco's modified Eagle's medium (Life Technologies, Inc.) supplemented with 8% dialyzed fetal calf serum. The quality and quantity of 35S-labeled MSP were analyzed by immunoprecipitation and SDS-PAGE under reducing and non-reducing conditions.

Binding and Competition Assays with 35S-Labeled MSP-- MDCK-RE7 cells with stably expressed RON receptor were used. The parental MDCK cell line without detectable expression of RON was used as a negative control. Five ml of supernatant containing equal concentrations of 35S-labeled wild type or mutant MSP were added to 5 × 106 RE7 or MDCK cells. Cells were equilibrated for 4 h at 4 °C. After equilibration, cells were washed 3 times with phosphate-buffered saline and lysed in lysis buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 10% glycerol, 1 mM EDTA, 1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 100 mM NaF, 1% Triton X-100, 10 µg/ml leupeptin, 10 units/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride). After clarification, lysates were immunoprecipitated by equilibration overnight at 4 °C with rabbit anti-MSP antibodies coupled to Sepharose. Then immunoprecipitates were washed 3 times with HNTG buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 10% glycerol, 0.1% Triton X-100) and analyzed by SDS-PAGE. Protein bands were detected by radioautography. For competition assays, 50 nM unlabeled recombinant human MSP or free alpha  or beta  chains were equilibrated with cells together with 35S-labeled MSP culture supernatants.

Binding of Free alpha  Chain to RON Receptor-- RE7 cells (5 × 106/well) with stably expressed RON receptor and parental MDCK cells as a negative control were equilibrated for 4 h at 4 °C in 5 nM free recombinant alpha  chain or MSP. Cells were then washed, and cell lysates were processed as described above, except that detection of protein bands was by immunoblotting with polyclonal rabbit anti-MSP antibodies.

RON-ELISA-- ELISA microtiter plates were coated overnight at 4 °C with the recombinant mouse MSP receptor RON/Fc (rmRON/Fc) chimera (R & D Systems, Inc.) (100 µl/well at 0.5 µg/ml in carbonate-bicarbonate buffer, pH 9.6). Nonspecific binding sites were blocked with 1% bovine serum albumin for 1 h at 37 °C. RON-coated ELISA plates were then incubated for 2 h with a series of 2-fold dilutions of human recombinant MSP (highest concentration 6.4 nM), free beta  chain (highest concentration 8 nM) or free alpha  chain (highest concentration 320 nM). ELISA plates were washed 3 times with TBS/Tween 20 after this and subsequent steps. Plates were then incubated with rabbit polyclonal anti-MSP for an additional 2 h. The rabbit anti-MSP antibodies recognize MSP and separate free chains with comparable sensitivity, as determined by direct ELISA in which microtiter wells were coated with MSP or free alpha  or beta  chain standards (data not shown). Bound rabbit anti-MSP was detected by equilibration with alkaline phosphatase-conjugated anti-rabbit IgG. Substrate 104 (Sigma) was used for quantifying alkaline phosphatase activity. Absorbance at 405 nM was measured with an ELISA reader. At least three independent experiments were performed. To quantify ligand binding affinity, EC50 values were calculated by using a four-parameter nonlinear fitting algorithm (31).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Model of the Serine Protease Domain of MSP-- The structural core of all chymotrypsin-like serine proteases is composed of two six-stranded beta  barrels, with the active site in a crevice between these two domains. MSP and HGF beta  chains have 48% sequence identity (Fig. 1) and higher than 30% sequence similarity to several mammalian serine proteases. Features in common include the same bilobed core, several surface loops, and a C-terminal helix (Fig. 2A). Furthermore, despite loss of enzymatic activity because of catalytic triad mutations, the geometry of the regions of MSP that correspond to the active site of serine proteases has been conserved. This includes mutated catalytic triad residues Gln522(57),3 Gln568(102), and Tyr661(195) (colored magenta in Figs. 1 and 2) at the junction of the beta  barrels, the same conformation of the Gly655(189)-Asp660(194) segment (colored violet) necessary for the formation of an oxyanion hole and a mature substrate specificity pocket. The critical interaction maintaining active site architecture, a salt bridge between Asp660(194) and the NH3+ group from the N-terminal Val of the beta  chain, is conserved.


View larger version (65K):
[in this window]
[in a new window]
 
Fig. 1.   Sequence alignment of bovine trypsin and serine protease domains of HGF and MSP. Conserved cysteines are marked in yellow; sequence homology between HGF and MSP is shown in green. Residues corresponding to the catalytic triad are shown in magenta. Numbering at the top corresponds to that of 2PTN entry in the Protein Data Bank. The open and filled bars under the sequence show the locations of beta  strands and helices, respectively.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 2.   A ribbon representation of the three-dimensional model of MSP serine protease domain. beta -Strands and C-terminal alpha  helix are shown in orange. Surface loop 1 (colored green) contains exclusively hydrophobic amino acids Leu, Leu, Ala, Pro, and Val. Three Arg residues from loop 2 (red) and three from loop 3 (red) form a prominent cluster of positive charge on the MSP surface. Segments with conformation significantly different from that of chymotrypsinogen, 484(16)-489(21) and 645(189)-660(194) are colored violet. Side chains of several key amino acids are also shown: mutated catalytic triad, Gln522(57), Gln568(102), Tyr661(195) in magenta; Glu648(184) and Asn682(216) buried in the S1 substrate binding pocket in azure; cluster of Arg residues in dark blue; carbon atoms of residues critical for zymogen activation, Val484(16), Asp660(194), and His505(40) in green. B, close-up of the region corresponding to the S1 specificity pocket of trypsin with the side chains of critical residues. Coloring as in A.

The residues critical for zymogen activation (for a review see Ref. 32) are also conserved in MSP, suggesting that conversion to the biologically active growth factor conformation mirrors the mechanism of zymogen activation. In the zymogen form of the chymotrypsin-like enzymes, the active site cleft is not completely formed. His505(40) interacts with Asp660(194), and the adjacent segment Gly655(189)-Asp660(194) is oriented to the interior of the zymogen. Upon activation, Asp660(194) forms the salt bridge noted above with the newly liberated N terminus, and segment Gly655(189)-Asp660(194) (colored violet in Fig. 2A) moves outward toward solvent to complete the active site cleft.

Surface loop features specific for MSP are noted in the legend of Fig. 2A. A detailed view of the region of MSP corresponding to the substrate binding pocket and catalytic triad is shown in Fig. 2B. Several features distinguish MSP from trypsin in this region as follows: 1) The entrance to the large cylindrical S1 pocket is blocked in MSP by Asn682(216) and Ala692(226), in contrast to trypsin, which has Gly residues at these positions. The conformation of Asn682(216) is stabilized by interaction with Glu648(184) buried inside the pocket. 2) Residue 655 in the base of the pocket in MSP is Gly, whereas in trypsin it is Asp, which interacts with the scissile bond Lys of the substrate. Thus, the model suggests that the receptor binding region of MSP does not include the base of the S1 pocket but involves the entrance.

Characterization of MSP Produced by CHO Cells Stably Transfected with Wild Type and Mutated MSP cDNAs-- Two MSP mutants were generated, a double mutant of residues that stabilize the shape of the S1 pocket (E648G/N682G) and a mutation of Arg683 (R683Q), adjacent to the entrance to the S1 pocket. Wild type and mutated MSP cDNAs were cloned into the eukaryotic expression vector pCl-neo, and stable CHO cell transfectants were generated. Serum-containing medium from the transfected cells was used as a source of wild type and mutant MSP. We selected clones that produced equal amounts of wild type or mutant MSP, and by sandwich ELISA the concentration in the medium was 0.5 nM (data not shown). The products were further characterized by SDS-PAGE. Culture fluids from 35S-metabolically labeled CHO cell transfectants were immunoprecipitated by rabbit anti-MSP antibodies and analyzed by SDS-PAGE under non-reducing and reducing conditions (Fig. 3). In confirmation of the sandwich ELISA results, the intensity of the bands in Fig. 3 shows that the selected CHO cell clones produce comparable amounts of wild type or mutated MSP. SDS-PAGE under reducing conditions shows that there is no 80-kDa pro-MSP in CHO supernatants. Only two bands at molecular mass positions of approximately 60 and 30 kDa corresponding to MSP alpha  and beta  chains were visualized (Fig. 3B). This is due to the fact that recombinant pro-MSP is cleaved to MSP in supernatants of CHO cells cultured in medium containing serum (17). The absence of an 80-kDa band under non-reducing conditions (Fig. 3A) demonstrates that the alpha  and beta  chains of these recombinant products are not disulfide-linked, in contrast to alpha beta chain heterodimeric native MSP. This is due to the fact that in recombinant pro-MSP, beta  chain Cys588 may form an intrachain disulfide with Cys672 instead of with alpha  chain Cys468 (19, 33).


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 3.   Analysis by SDS-PAGE under non-reduced (A) and reduced (B) conditions of 35S-labeled MSP produced by CHO cells. CHO cells with stably expressed wild type (WT) or mutated MSP were metabolically labeled with [35S]methionine and -cysteine. 35S-Labeled MSP was immunoprecipitated from 1 ml of CHO tissue culture supernatants by rabbit anti-MSP antibodies coupled to Sepharose beads. Immunoprecipitated proteins were separated by 4-12% gradient SDS-PAGE under non-reducing (A) and reducing (B) conditions and detected by radioautography. Arrows indicate the position of MSP alpha  and beta  chains. Their presence under non-reducing conditions shows that they are not disulfide-linked. The band at about 90 kDa is not an MSP protein.

Binding of Wild Type and Mutated MSP beta  Chain to RON-- To determine the capacity of wild type and mutated MSP beta  chain to interact with receptor, MDCK-RE7 cells with overexpressed RON and parental MDCK cells as a control were equilibrated with 35S-labeled CHO cell supernatants containing 0.5 nM free alpha  and beta  chain. After equilibration, cells were washed and lysed. Cell-bound MSP chains were immunoprecipitated by rabbit anti-MSP antibodies which recognize both alpha  and beta  chains (28). Precipitated MSP chains were analyzed by SDS-PAGE, and protein bands were visualized by radioautography. Results for RE7 lysates (Fig. 4A) showed an intense wild type MSP beta  chain band, a faint band for beta  chain mutated in the S1 pocket, and no band for the R683Q mutant. Densitometry of the beta  chain bands showed that the amount of double mutant E648G/N682G bound was about 50 times less than bound wild type beta  chain; no R683Q band was detected. There was no MSP beta  chain binding to parental MDCK cells, which do not express detectable RON (9). Interaction of 35S-labeled beta  chain from CHO supernatants was inhibited by either unlabeled MSP or free beta  chain (Fig. 4B). This result suggested that we were observing saturable binding of beta  chain to RON, a conclusion supported by the absence of binding to MDCK cells. The diminished or absent beta  chain mutant bands in Fig. 4A therefore reflect diminished or undetectable binding of the mutants to RON.


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 4.   A, binding of 35S-labeled wild type (WT) and mutated MSP to RON. MDCK-RE7 cells (5 × 106) with stably expressed RON receptor or parental MDCK cells without detectable RON were equilibrated for 4 h at 4 °C in 5 ml of CHO tissue culture supernatants containing 35S-labeled wild type or mutated MSP. Cell-bound 35S-MSP was immunoprecipitated with rabbit anti-MSP antibodies coupled to Sepharose beads. Immunoprecipitated proteins were separated by 4-12% gradient SDS-PAGE, and protein bands were visualized by radioautography. B, MSP and free beta  chain compete with 35S-labeled wild type or mutated MSP for binding to RON. MDCK-RE7 cells were equilibrated for 4 h at 4 °C in 5 ml of CHO supernatants containing 35S-labeled wild type or mutated MSP in the presence of excess unlabeled MSP, alpha  chain or beta  chain. Cell-bound labeled MSP was detected as described for A.

Binding of Free alpha  Chain to MDCK-RE7 Cells-- In addition to the beta  chain, we detected binding of free alpha  chain to RON-expressing cells (Fig. 4A, upper band). Reasons to suggest that the observed band represents MSP alpha  chain are as follows: 1) an appropriate molecular mass; 2) no band in the case of supernatants from metabolically labeled CHO cells transfected with vector alone, which therefore do not express MSP; and 3) no band with supernatants of MSP-transfected cells that were equilibrated with parental MDCK cells, which do not express RON. Comparison of the band intensities in Fig. 4A shows that the amount of bound alpha  chain is only a small fraction of the amount of bound beta  chain. Therefore it was important to determine whether the band reflected binding of free alpha  chain or a small amount of MSP alpha beta chain heterodimer binding via the beta  chain. Two facts weighed against the latter possibility. First, as noted above, SDS-PAGE of metabolically labeled transfected CHO cell supernatants did not reveal any trace of alpha beta chain MSP. Second, despite no sign of MSP mutant R683Q beta  chain binding, the alpha  chain band was detectable (Fig. 4A). To obtain independent evidence that free alpha  chain can interact with RON, a binding assay of purified recombinant alpha  chain was performed. MDCK-RE7 cells or MDCK cells as a control were equilibrated for 4 h at 4 °C with 5 nM free recombinant alpha  chain or disulfide-linked alpha beta chain MSP. Then bound alpha beta chain MSP or alpha  chain was immunoprecipitated with mouse monoclonal 2 S anti-MSP, which recognizes only alpha  chain (28). Immunoprecipitated alpha  chain was detected on a blot with rabbit anti-MSP antibodies after SDS-PAGE and transfer of proteins to a nitrocellulose membrane. Fig. 5A shows binding of free alpha  chain to RE-7 cells, which is a small fraction of the amount of alpha  chain detected after alpha beta chain MSP was equilibrated with the cells. In both cases, binding is RON-dependent, as shown by the absence of bands from MDCK cell lysates. It was also important to consider the possibility that the bound alpha  chain line came from binding of a small amount of alpha beta MSP that contaminates the alpha  chain preparation. This was ruled out by SDS-PAGE of the same cell immunoprecipitates under non-reducing conditions. If the alpha  chain detected in Fig. 5A (under reducing conditions) were due entirely to bound alpha beta chain contaminating the alpha  chain preparation, non-reducing SDS-PAGE should show an alpha beta line and no alpha . The converse is the case (Fig. 5B). For the alpha  chain lane, at an ECL exposure that shows an alpha  chain line comparable in intensity to that of Fig. 5A, there is no detectable alpha beta line. At longer exposure times we see an alpha beta line and a much more intense alpha  chain line. The latter reflects binding of free alpha  chain to the RE-7 cells; the former is due to the small amount of alpha beta chain contaminating the alpha  chain preparation and is a small fraction of the total bound alpha  chain.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 5.   Interaction of MSP free alpha  chain with RON. MDCK-RE7 cells or MDCK cells as a control were equilibrated for 4 h at 4 °C in 5 nM recombinant MSP or free alpha  chain. Cell-bound MSP or alpha  chain was immunoprecipitated (IP) by mouse monoclonal anti-MSP antibody (that reacts with an alpha  chain epitope) coupled to Sepharose. Immunoprecipitated proteins were separated by 7.5% SDS-PAGE under reducing (A) and non-reducing (B) conditions. Protein bands were detected by Western blotting (WB) with rabbit anti-MSP antibodies. For the MSP standard, 5 nM MSP was directly immunoprecipitated with mouse monoclonal anti-MSP. The left and right blots in B illustrate results of short and long exposures.

Quantitative Analysis of MSP, alpha  and beta  Chain Binding to the RON Receptor-- In addition to the above experiments on binding of MSP and its chains to cells expressing RON, we quantified by sandwich ELISA the binding of disulfide-linked alpha beta chain MSP and free alpha  and beta  chains to recombinant mouse RON receptor adsorbed to wells of a microtiter plate. Binding of each ligand was tested in duplicate in three separate experiments, and concentration-dependent binding curves were generated (Fig. 6). Mean EC50 values calculated from curves of the three experiments (31) are shown in the inset of Fig. 6. Disulfide-linked alpha beta chain MSP has a somewhat higher affinity for RON than free beta  chain, a result comparable to binding data for RON-expressing cells (24). In contrast, free alpha  chain binds to RON with a much lower affinity, as reflected in an EC50 that is 2 orders of magnitude higher than the value for MSP. Thus, MSP has two separate binding sites with high and low affinity, located in beta  and alpha  chains, respectively.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 6.   Concentration-dependent binding of recombinant disulfide-linked alpha beta chain MSP and free alpha  and beta  chains to the RON receptor adsorbed to wells of a microtiter plate and measured in an ELISA as described under "Experimental Procedures." Each value represents the mean ± S.E. of three independent experiments.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The MSP beta  chain three-dimensional model enabled us to consider possible loci for RON high affinity binding by analogy to substrate-enzyme interactions in the family of chymotrypsin-like serine proteases. In zymogens of the family the catalytic triad is formed, but the substrate-binding site is not fully shaped. MSP is able to bind RON with high affinity only after proteolytic cleavage, which in zymogens causes conformational changes leading to formation of a mature binding site (Fig. 2). Thus residues critical for receptor binding should correspond to those that define the subsite preference at the scissile bond of substrate. According to the model, the S1 pocket in MSP is filled by interacting pair Glu648 and Asn682, leaving only a shallow cavity for interaction with the substrate side chain. In addition to a double mutant of the Glu/Asn pair (E648G/N682G), we made a single mutant of Arg683 located at the entrance to the S1 pocket. We mutated Arg683 to Gln, which is also hydrophilic and has side chain length comparable to that of Arg. Thus mutation of Arg683 to Gln was not expected to affect the structure of the beta  chain. The fact that mutation of Arg683 alone completely abolished beta  chain binding to RON (Fig. 4A) suggests that this residue is directly involved in receptor binding. Such a profound effect caused by a single site mutation is not surprising in view of the fact that mutation of a single residue of human growth hormone receptor (34) or HGF alpha  chain (see below) caused loss of binding to their respective ligands. Binding of beta  chain mutant E648G/N682G is about 50 times less than the binding of beta  chain wild type. The diminished binding of the double mutant (E648G/N682G) suggests that these residues are required to stabilize the beta  chain structure in this region. Our results show that the region corresponding to an enzyme S1 site is essential for beta  chain binding to RON. Other features affecting specificity of MSP-receptor interactions may involve residues from loops 1-3 (shown in Fig. 2A), which influence substrate specificity and catalytic efficiency of the trypsin-like serine proteases (26). It is noteworthy that six Arg side chains from loops 2 and 3 form a prominent cluster of positive charge on the MSP beta  chain surface in the neighborhood of the S1 site.

We recently proposed that both HGF and MSP have two receptor binding sites of different affinity, one on the alpha  chain and one on the beta  chain, and that Met and RON dimerization can be induced by a single ligand molecule (27). The site on the beta  chain becomes available for binding only after proteolytic cleavage of the single chain precursors. For HGF, the high affinity site is on the alpha  chain and the postulated low affinity site is on the beta  chain. The converse is the case for MSP. Comparison of our model of the MSP beta  chain structure with that of the HGF beta  chain shows that, in contrast to MSP, the opening of the HGF S1 pocket is not blocked; and there are differences in the surface loops, as described in the legend of Fig. 2A. These differences in the S1 pocket and neighboring surface loops could account for the inability of HGF to bind via its beta  chain to RON (35).

This communication provides the first evidence that free MSP alpha  chain interacts with the RON receptor (Figs. 4A, 5, and 6). We previously reported undetectable binding to RON-expressing cells by a 125I-labeled aliquot of the same alpha  chain preparation used in the current study (24). We attribute this to a lower sensitivity of the former method. After cells were equilibrated with equimolar concentrations of free alpha  and beta  chains, bound alpha  chain was less than 10% of bound beta  chain (determined by densitometry of the blot shown in Fig. 4A). The published binding curves of iodinated MSP or beta  chain show that 10% of the observed values would be indistinguishable from background (24). We quantified binding of MSP and its free alpha  and beta  chains to recombinant RON adsorbed to microtiter wells. Results show that MSP has two binding sites with low (EC50 = 16.9 nM) and high (EC50 = 0.25 nM) affinity, located in alpha  and beta  chains respectively.

Despite binding of free alpha  chain or beta  chain to RON, neither chain can replicate the action of the disulfide-linked heterodimer. Wang et al. (24) reported that whereas mature MSP caused tyrosine phosphorylation of RON and a cellular biological response, these effects were not induced by strongly binding free beta  chain or by alpha  chain. In our case, the low level of alpha  chain binding to RON-expressing cells also did not induce RON tyrosine phosphorylation (data not shown). How does alpha beta chain MSP cause RON dimerization? The fact that the alpha  chain and beta  chain are each capable of interacting with RON suggests that MSP is bivalent, with a high affinity locus on the beta  chain and a low affinity site on the alpha  chain. The contribution of the alpha  chain to the binding strength of MSP to RON was suggested by an MSP binding Kd that was significantly lower than the Kd for free beta  chain (24). As noted above, we proposed that a RON dimer could be formed by a single MSP molecule that could bind to RON via the beta  chain, after which a second RON could interact with the alpha  chain. The converse sequence was suggested for HGF. This is the model that has been confirmed for induction of receptor dimerization by growth hormone (36). The finding that the alpha  chain can bind to RON supports our proposed model.

    ACKNOWLEDGEMENTS

We thank Dr. Tom L. Blundell and colleagues for providing us with the coordinates of the HGF beta  chain three-dimensional model. We also thank Dr. Teizo Yoshimura for the MSP cDNA and Alison Skeel for technical assistance.

    FOOTNOTES

* This work was supported in part by funds from the National Cancer Institute, DHHS, under contract with ABL (to M. M.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: NCI-FCRDC, Bldg. 560/Rm. 12-46, Frederick, MD 21702. Tel.: 301-846-1560; Fax: 301-846-6145; E-mail:danilkovitch@mail.ncifcrf.gov.

2 A. Skeel and E. J. Leonard, unpublished data.

3 MSP residue numbers in the text are followed in parentheses by the corresponding bovine trypsin residue number.

    ABBREVIATIONS

The abbreviations used are: MSP, macrophage-stimulating protein; HGF/SF, hepatocyte growth factor/scatter factor; MDCK, Madin-Darby canine kidney; CHO, Chinese hamster ovary; ELISA, enzyme-linked immunosorbent assay; PAGE, polyacrylamide gel electrophoresis.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Skeel, A., Yoshimura, T., Showalter, S., Tanaka, S., Appella, E., and Leonard, E. (1991) J. Exp. Med. 173, 1227-1234[Abstract/Free Full Text]
2. Yoshimura, T., Yuhki, N., Wang, M.-H., Skeel, A., and Leonard, E. J. (1993) J. Biol. Chem. 268, 15461-15468[Abstract/Free Full Text]
3. Han, S., Stuart, L. A., and Degen, S. J. F. (1991) Biochemistry 30, 9768-9780[CrossRef][Medline] [Order article via Infotrieve]
4. Leonard, E. J. (1997) in Plasminogen-related Growth Factors (Bock, G. R. , and Goode, J. A., eds) , pp. 183-191, John Wiley & Sons, Inc., New York
5. Leonard, E. J., and Skeel, A. (1976) Exp. Cell Res. 102, 434-438[CrossRef][Medline] [Order article via Infotrieve]
6. Wang, M.-H., Cox, G. W., Yoshimura, T., Sheffler, L. A., Skeel, A., and Leonard, E. J. (1994) J. Biol. Chem. 269, 14027-14031[Abstract/Free Full Text]
7. Danilkovitch, A., and Leonard, E. J. (1999) J. Leukocyte Biol. 65, 345-348[Abstract]
8. Ronsin, C., Muscatelli, F., Mattei, M. G., and Breathnach, R. (1993) Oncogene 8, 1195-1202[Medline] [Order article via Infotrieve]
9. Wang, M.-H., Ronsin, C., Gesnel, M.-C., Coupey, L., Skeel, A., Leonard, E. J., and Breathnach, R. (1994) Science 266, 117-119[Abstract/Free Full Text]
10. Wang, M.-H., Iwama, A., Skeel, A., Suda, T., and Leonard, E. J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 3933-3937[Abstract/Free Full Text]
11. Iwama, A., Wang, M.-H., Yamaguchi, N., Okano, K., Sudo, T., Gervais, F., Morissette, C., Leonard, E. J., and Suda, T. (1995) Blood 86, 3394-3403[Abstract/Free Full Text]
12. Matsumoto, K., and Nakamura, T. (1992) Crit. Rev. Oncog. 3, 27-54[Medline] [Order article via Infotrieve]
13. Park, M., Dean, M., Kaul, K., Braun, M. J., Gonda, M. A., and Vande Woude, G. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 6379-6383[Abstract/Free Full Text]
14. Matsumoto, K., and Nakamura, T. (1997) Biochem. Biophys. Res. Commun. 239, 639-644[CrossRef][Medline] [Order article via Infotrieve]
15. Jeffers, M., Rong, S., and Woude, G. F. (1996) J. Mol. Med. 74, 505-513[CrossRef][Medline] [Order article via Infotrieve]
16. Schmidt, L., Duh, F. M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., Allikmets, R., Chidambaram, A., Bergerheim, U. R., Feltis, J. T., Casadevall, C., Zamarron, A., Bernues, M., Richard, S., Lips, C. J., Walther, M. M., Tsui, L. C., Geil, L., Orcutt, M. L., Stackhouse, T., and Zbar, B. (1997) Nat. Genet. 16, 68-73[CrossRef][Medline] [Order article via Infotrieve]
17. Wang, M.-H., Yoshimura, T., Skeel, A., and Leonard, E. J. (1994) J. Biol. Chem. 269, 3436-3440[Abstract/Free Full Text]
18. Bezerra, J. A., Witte, D. P., Aronow, B. J., and Degen, S. J. (1993) Hepatology 18, 394-399[CrossRef][Medline] [Order article via Infotrieve]
19. Yoshikawa, W., Hara, H., Takehara, T., Shimonishi, M., Sakai, H., Shimizu, N., Shimizu, S., Wang, M.-H., Hagiya, M., Skeel, A., and Leonard, E. J. (1999) Arch. Biochem. Biophys. 363, 356-360[CrossRef][Medline] [Order article via Infotrieve]
20. Nanney, L. B., Skeel, A., Luan, J., Polis, S., Richmond, A., Wang, M.-H., and Leonard, E. J. (1998) J. Invest. Dermatol. 111, 573-581[CrossRef][Medline] [Order article via Infotrieve]
21. Donate, L. E., Gherardi, E., Srinivasan, N., Sowdhamini, R., Aparicio, S., and Blundell, T. L. (1994) Protein Sci. 3, 2378-2394[Abstract]
22. Sakata, H., Stahl, S. J., Taylor, W. G., Rosenberg, J. M., Sakaguchi, K., Wingfield, P. T., and Rubin, J. S. (1997) J. Biol. Chem. 272, 9457-9463[Abstract/Free Full Text]
23. Lokker, N. A., Presta, L. G., and Godowski, P. J. (1994) Protein Eng. 7, 895-903[Abstract/Free Full Text]
24. Wang, M. H., Julian, F. M., Breathnach, R., Godowski, P. J., Takehara, T., Yoshikawa, W., Hagiya, M., and Leonard, E. J. (1997) J. Biol. Chem. 272, 16999-17004[Abstract/Free Full Text]
25. Waltz, S. E., McDowell, S. A., Muraoka, R. S., Air, E. L., Flick, L. M., Chen, Y. Q., Wang, M. H., and Degen, S. J. (1997) J. Biol. Chem. 272, 30526-30537[Abstract/Free Full Text]
26. Perona, J. J., and Craik, C. S. (1997) J. Biol. Chem. 272, 29987-29990[Free Full Text]
27. Miller, M., and Leonard, E. J. (1998) FEBS Lett. 429, 1-3[CrossRef][Medline] [Order article via Infotrieve]
28. Wang, M.-H., Skeel, A., Yoshimura, T., Copeland, T. D., Sakaguchi, K., and Leonard, E. J. (1993) J. Leukocyte Biol. 54, 289-295[Abstract]
29. Jones, A. (1985) Methods Enzymol. 115, 157-171[Medline] [Order article via Infotrieve]
30. Brunger, A. (1992) X-PLOR: A System for X-ray Crystallography and NMR, version 3.1 , Yale University Press, New Haven, CT
31. Jin, L., Fendly, B. M., and Wells, J. A. (1992) J Mol. Biol. 226, 851-865[CrossRef][Medline] [Order article via Infotrieve]
32. Khan, A. R., and James, M. N. (1998) Protein Sci. 7, 815-836[Abstract]
33. Wahl, R. C., Costigan, V. J., Batac, J. P., Chen, K., Cam, L., Courchesne, P. L., Patterson, S. D., Zhang, K., and Pacifici, R. E. (1997) J. Biol. Chem. 272, 15053-15056[Abstract/Free Full Text]
34. Clackson, T., and Wells, J. A. (1995) Science 267, 383-386[Abstract/Free Full Text]
35. Wang, M.-H., Iwama, A., Dlugosz, A. A., Sun, Y., Skeel, A., Yuspa, S. H., Suda, T., and Leonard, E. J. (1996) Exp. Cell Res. 226, 39-46[CrossRef][Medline] [Order article via Infotrieve]
36. de Vos, A. M., Ultsch, M., and Kossiakoff, A. A. (1992) Science 255, 306-312[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
D. Kirchhofer, X. Yao, M. Peek, C. Eigenbrot, M. T. Lipari, K. L. Billeci, H. R. Maun, P. Moran, L. Santell, C. Wiesmann, et al.
Structural and Functional Basis of the Serine Protease-like Hepatocyte Growth Factor {beta}-Chain in Met Binding and Signaling
J. Biol. Chem., September 17, 2004; 279(38): 39915 - 39924.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Angeloni, A. Danilkovitch-Miagkova, A. Miagkov, E. J. Leonard, and M. I. Lerman
The Soluble Sema Domain of the RON Receptor Inhibits Macrophage-stimulating Protein-induced Receptor Activation
J. Biol. Chem., January 30, 2004; 279(5): 3726 - 3732.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M.-H. Wang, D. Wang, and Y.-Q. Chen
Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase
Carcinogenesis, August 1, 2003; 24(8): 1291 - 1300.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow